Canada Allergy Diagnostics And Therapeutics Market Size & Outlook
Canada allergy diagnostics and therapeutics market, 2018-2030 (US$M)
Related Markets
Canada allergy diagnostics and therapeutics market highlights
- The Canada allergy diagnostics and therapeutics market generated a revenue of USD 1,261.8 million in 2023 and is expected to reach USD 2,108.5 million by 2030.
- The Canada market is expected to grow at a CAGR of 7.6% from 2024 to 2030.
- In terms of segment, inhaled was the largest revenue generating allergen type in 2023.
- Food is the most lucrative allergen type segment registering the fastest growth during the forecast period.
Allergy diagnostics and therapeutics market data book summary
| Market revenue in 2023 | USD 1,261.8 million |
| Market revenue in 2030 | USD 2,108.5 million |
| Growth rate | 7.6% (CAGR from 2023 to 2030) |
| Largest segment | Inhaled |
| Fastest growing segment | Food |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Inhaled, Drug, Other Allergens, Food |
| Key market players worldwide | Rohm Co Ltd, Thermo Fisher Scientific Inc, PerkinElmer, BioMerieux SA, Siemens Healthineers AG ADR, Omega Healthcare Investors Inc, Danaher Corp, Alcon Inc, AbbVie Inc, Sanofi SA, Allergy Therapeutics PLC, Pfizer Inc, Teva Pharmaceutical Industries Ltd, GSK PLC, Sun Pharmaceutical Industries, Roche Holding AG, Merck & Co Inc, Astellas Pharma Inc, Epigenomics AG |
Other key industry trends
- In terms of revenue, Canada accounted for 4.0% of the global allergy diagnostics and therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. allergy diagnostics and therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 2,108.5 million by 2030.
Inhaled was the largest segment with a revenue share of 45.55% in 2023. Horizon Databook has segmented the Canada allergy diagnostics and therapeutics market based on inhaled, drug, other allergens, food covering the revenue growth of each sub-segment from 2018 to 2030.
Some of the main drivers of the market expansion are expanding use of in vitro diagnostic tests, advancements in medical insurance programs, and rising demand for better healthcare.
Stringent healthcare policies and awareness programs are being implemented by governments in the region, which is motivating market participants to create tests and drugs that are useful and patient-friendly. Furthermore, the launch of new products is boosting market growth.
For instance, in March 2022, Miravo Healthcare announced the Canadian commercial launch of Blexten for patients 4 years of age and above for the treatment of the symptoms of seasonal allergic rhinitis and chronic spontaneous urticaria. Some of the key players in the market are Danaher, Siemens Healthcare GmbH, Sanofi, and Merck & Co., Inc.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Allergy Diagnostics And Therapeutics Market Scope
Allergy Diagnostics And Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Canada allergy diagnostics and therapeutics market size, by allergen type, 2018-2030 (US$M)
Canada Allergy Diagnostics And Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
